Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 1
1981 7
1983 3
1985 2
1986 3
1987 8
1988 4
1989 8
1990 6
1991 7
1992 11
1993 3
1994 13
1995 8
1996 4
1997 6
1998 9
1999 14
2000 25
2001 15
2002 17
2003 15
2004 16
2005 8
2006 10
2007 16
2008 11
2009 11
2010 14
2011 14
2012 9
2013 9
2014 9
2015 4
2016 4
2017 8
2018 8
2019 13
2020 10
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

352 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ; EMPA-TROPISM (ATRU-4) Investigators. Santos-Gallego CG, et al. Among authors: badimon jj. J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. doi: 10.1016/j.jacc.2020.11.008. Epub 2020 Nov 13. J Am Coll Cardiol. 2021. PMID: 33197559
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Santos-Gallego CG, et al. Among authors: badimon jj. J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056. J Am Coll Cardiol. 2019. PMID: 30999996 Free article.
Metabolism of the failing heart and the impact of SGLT2 inhibitors.
Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ. Garcia-Ropero A, et al. Among authors: badimon jj. Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):275-285. doi: 10.1080/17425255.2019.1588886. Epub 2019 Mar 11. Expert Opin Drug Metab Toxicol. 2019. PMID: 30822172 Review.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. Naghavi M, et al. Among authors: badimon jj. Circulation. 2003 Oct 7;108(14):1664-72. doi: 10.1161/01.CIR.0000087480.94275.97. Circulation. 2003. PMID: 14530185 Review.
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ. Santos-Gallego CG, et al. Among authors: badimon jj. Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95. doi: 10.1007/s10557-018-06850-0. Cardiovasc Drugs Ther. 2019. PMID: 30675708
Estimation of the major cardiovascular events prevention with Inclisiran.
Cordero A, Santos-Gallego CG, Fácila L, Rodríguez-Mañero M, Bertomeu-González V, Castellano JM, Seijas-Amigo J, Núñez J, Zuazola P, González-Juanatey JR, Badimon JJ. Cordero A, et al. Among authors: badimon jj. Atherosclerosis. 2020 Nov;313:76-80. doi: 10.1016/j.atherosclerosis.2020.09.021. Epub 2020 Sep 25. Atherosclerosis. 2020. PMID: 33032236
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, Picatoste B, Vargas-Delgado AP, Flores-Umanzor EJ, Sanz J, Fuster V, Badimon JJ. Santos-Gallego CG, et al. Among authors: badimon jj. JACC Cardiovasc Imaging. 2021 Feb;14(2):393-407. doi: 10.1016/j.jcmg.2020.07.042. Epub 2020 Oct 29. JACC Cardiovasc Imaging. 2021. PMID: 33129742
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, Farhan S, Gurbel P, Gibson CM, Fuster V, Mehran R, Badimon JJ. Baber U, et al. Among authors: badimon jj. J Am Coll Cardiol. 2020 Feb 18;75(6):578-586. doi: 10.1016/j.jacc.2019.11.056. J Am Coll Cardiol. 2020. PMID: 32057371 Free article. Clinical Trial.
The anti-inflammatory effects of SGLT inhibitors.
García-Ropero Á, Santos-Gallego CG, Badimon JJ. García-Ropero Á, et al. Among authors: badimon jj. Aging (Albany NY). 2019 Aug 25;11(16):5866-5867. doi: 10.18632/aging.102175. Epub 2019 Aug 25. Aging (Albany NY). 2019. PMID: 31449492 Free PMC article. No abstract available.
352 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page